Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFKB1 | P19838 | 1/20 | 0.30 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.30 |
| ▸ | RELA | Q04206 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5613785 | 1.00 | NFKB1 (0.30) | NFKB1NFKB2RELA | |
| SCHEMBL2953173 | 1.00 | NFKB1 (0.30) | NFKB1NFKB2RELA | |
| SCHEMBL968867 | 0.83 | NFKB1 (0.38) | NFKB1NFKB2RELA | |
| SCHEMBL968866 | 0.83 | NFKB1 (0.38) | NFKB1NFKB2RELA | |
| SCHEMBL852586 | 0.83 | NFKB1 (0.38) | NFKB1NFKB2RELA | |
| SCHEMBL13486701 | 0.76 | BACE1 (0.35) | — | |
| SCHEMBL4911804 | 0.73 | DUT (0.36) | — | |
| SCHEMBL4790841 | 0.73 | DUT (0.36) | — | |
| SCHEMBL15007568 | 0.72 | — | — | |
| SCHEMBL13734264 | 0.70 | NLRP3 (0.39) | NFKB1NFKB2RELA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8367735-B2 | Pharmaceutical compositions | CRAWFORD HEALTHCARE HOLDINGS LIMITED (GB) | 2013-02-05 | — | — | US | disclosed |
| US-20090325901-A1 | IMPROVEMENTS IN PHARMACEUTICAL COMPOSITIONS | ROSANTO PHARMACEUTICALS LTD. (GB) | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325901-A1 | IMPROVEMENTS IN PHARMACEUTICAL COMPOSITIONS | ARL1, RPS6KA2, ADSL | NFKB1 1698/4885NFKB2 752/4885RELA 2135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.